The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations

Author(s): Dearbhaile C. Collins, Maxime Chenard-Poirier, Juanita S. Lopez*

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 4 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Immunotherapy has led to a paradigm shift in the treatment of some malignancies, providing long-term, durable responses for a subset of patients with advanced cancers. Increasingly, research has identified links between the immune system and critical oncogenic growth factor pathways. The phosphoinositide 3-kinase (PI3K)-AKT-mTOR cascade is frequently hyperactivated in cancer, and plays an integral role in many cellular processes including tumour growth and survival and can underlie resistance to therapies.

In this review, we first summarize two key learnings from the initial studies of inhibitors of this pathway, including the profile of immune-related adverse events such as colitis, transaminitis and pneumonitis and the increased incidence of infections with the majority of agents that target the PI3K-AKT-mTOR pathway. We then discuss recent advances in our understanding of the role of this pathway in the tumour micro-environment, and in the regulation of innate and adaptive immune responses, and propose synergistic combination strategies with PI3K-network inhibitors and cancer immunotherapy.

Keywords: PI3K inhibitors, immunotherapy, combination therapy, PI3K pathway, micro-environment, cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 27 September, 2017
Page: [355 - 364]
Pages: 10
DOI: 10.2174/1568009617666170927114440
Price: $65

Article Metrics

PDF: 88
HTML: 19
PRC: 2